Angioedema‐like allergic contact dermatitis to castor oil

Sánchez-Guerrero, I.; Huertas, A.J.; López, María Aránzazu García; Carreño, A.; Mercedes, Ramírez; Pajarón, M. J.

doi:10.1111/j.1600-0536.2010.01733.x

Cited by 9 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The differential diagnosis for her reaction included angioedema and allergic contact dermatitis. Although there have been cases in the literature reporting angioedemalike allergic contact dermatitis after exposure to chemical compounds (5)(6)(7)(8), we favor a diagnosis of angioedema given the pertinent positives (generalized head and neck facial swelling) and pertinent negatives (absence of acute eczematous dermatitis and pruritus, even in treated areas). The patient and family were instructed to apply SADBE only to affected areas of the scalp every other night and to wash it off in the morning, but the patient had been applying it to all areas of the scalp nightly and leaving it on until after school.…”

Section: Discussionmentioning

confidence: 92%

Angioedema After Squaric Acid Treatment in a 6‐Year‐Old Girl

Chen

Carlberg

Kroshinsky

2016

Pediatric Dermatology

View full text Add to dashboard Cite

Alopecia areata (AA) involves the immune-related destruction of hair follicles, resulting in patches of complete hair loss, most often on the scalp. The topical sensitizer squaric acid dibutylester (SADBE) is a popular treatment option given its low side-effect profile, hair regrowth potential, and lack of cross-reactivity with other chemicals. We describe a unique case of a 6-year-old girl who developed angioedema after SADBE treatment for AA.

show abstract

Section: Discussionmentioning

confidence: 92%

Angioedema After Squaric Acid Treatment in a 6‐Year‐Old Girl

Chen

Carlberg

Kroshinsky

2016

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…Cases of allergic contact dermatitis from the oil, and from its derivatives, have occasionally been reported [5][6][7]. We here report 2 additional cases of allergic contact dermatitis from castor oil present in lip balms, whereas patch tests with hydrogenated castor oil 30% in petrolatum (pet.)…”

Section: Introductionmentioning

confidence: 83%

“…It is also used in pharmaceuticals (e.g., in laxatives) [5], as biofuel [10], and as a lubricant and for food flavoring [1,3,5].…”

Section: Discussionmentioning

confidence: 99%

Contact Allergy to Castor Oil, but Not to Castor Wax

Verheyden¹,

Rombouts²,

Lambert³

et al. 2017

Cosmetics

View full text Add to dashboard Cite

Ricinus communis (castor) seed oil (CAS 8001-79-4), a vegetable oil extracted from the seeds of Ricinus communis, is widely used in cosmetics and pharmaceuticals, and may be a cause of allergic contact dermatitis from these products. We present two patients with allergic contact dermatitis from cosmetics containing castor oil, in whom a correct diagnosis was achieved by patch testing castor oil 'as is'. PEGylated and/or hydrogenated derivatives (the latter formerly also available from patch test allergen suppliers) and/or cosmetics containing these specific derivatives did not result in contact allergy or allergic contact dermatitis. This observation might be relevant for the manufacturing of cosmetics and pharmaceuticals. In the future, further research into the allergenicity of castor oil and its numerous derivatives, and their optimal patch test concentrations, may be desirable.

show abstract

“…ADRs may be caused by a variety of mechanisms. While there are multiple studies that have previously documented injection site reaction with use of 17OHP for prevention of preterm birth 6,19 and patient hypersensitivity to other compounded progesterone products, [20][21][22][23] we are not aware of any other documented reports of acute coughing upon administration of compounded 17OHP.…”

Section: Discussionmentioning

confidence: 99%

“…Several different case reports describe castor oil-induced angioedema-like allergic reactions and other skin reactions; however, the commercial formulation is suspended in castor oil and was associated with significantly less ADR events in this study. [21][22][23] Another case report describes recurrent anaphylaxis, cyclic urticaria, and angioedema induced by immunoresponsiveness to progesterone itself; however, if progesterone was the offending agent, one would expect equal number of ADRs across product formulations in this dataset. 24 The potential mechanism of action for an ADR of acute coughing immediately following 17OHP administration is unclear.…”

Section: Discussionmentioning

confidence: 99%

Prevention of Preterm Labor with 17α-Hydroxyprogesterone (17OHP) Caproate: A Comparison of Adverse Drug Reaction Rates between Compounded and Commercial Formulations

Stone

Bobowski²,

Milikhiker

et al. 2017

Amer J Perinatol

View full text Add to dashboard Cite

Objective A commercial formulation of injectable 17α-hydroxyprogesterone (17OHP) for prevention of preterm birth was introduced in 2011; however, use of compounded formulations remains widespread. This study compared the frequency of adverse drug reactions (ADRs) associated with compounded versus commercial 17OHP formulations, aiding in provider assessment of 17OHP tolerability. Study Design A retrospective cohort evaluation of data obtained from the electronic medical record (EMR) of patients prescribed weekly 17OHP injections at an obstetric clinic between 2009 and 2015 was performed. A descriptive analysis characterized the frequency and proportion of ADRs associated with 17OHP administration. Patient differences between 17OHP formulations were identified with t-test, chi-square, or Fischer's exact tests. Results Of 175 patients included, 56% received commercial formulation and 44% received compounded formulation. ADRs occurred in 16 patients, all of whom received the compounded formulation (p < 0.001). The most common ADRs were injection site reaction (n = 7) and acute coughing following 17OHP administration (n = 6). Of patients with an ADR, 63% discontinued all medication therapy for prevention of preterm birth or changed to an alternative therapy. Conclusion Comparison of ADR rates between compounded and commercial formulation differed significantly. In addition to food and drug administration (FDA) compliance, providers may consider preferential use of the commercial formulation, since 21% of women receiving compounded product experienced an ADR.

show abstract

Angioedema‐like allergic contact dermatitis to castor oil

Cited by 9 publications

References 7 publications

Angioedema After Squaric Acid Treatment in a 6‐Year‐Old Girl

Angioedema After Squaric Acid Treatment in a 6‐Year‐Old Girl

Contact Allergy to Castor Oil, but Not to Castor Wax

Prevention of Preterm Labor with 17α-Hydroxyprogesterone (17OHP) Caproate: A Comparison of Adverse Drug Reaction Rates between Compounded and Commercial Formulations

Contact Info

Product

Resources

About